NCT07701993 Efimosfermin alfa MASH Cirrhosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07701993—A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) (NEBULA-1)—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07701993 is a hot trial to watch

MASH Cirrhosis is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. NCT07701993 is notable because it tests Efimosfermin alfa in a Phase 3 design with Time from randomization to an adjudicated composite liver-related clinical outcome as a primary decision variable. The wider PatSnap topic query returned 474 trial records and 349 result records, so differentiation depends on evidence quality rather than activity alone.

PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. The primary endpoint—Time from randomization to an adjudicated composite liver-related clinical outcome—determines what uncertainty this study can resolve. The reported time frame is From Randomization (Day 1) to Week 356 (end of treatment). Enrollment of 1740 participants and geography in Not reported shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

Benchmark readouts in the same clinical field

• Self-Reported Cognitive Function in Metabolic Dysfunction–associated Steatotic Liver Disease and Metabolic Dysfunction–associated Steatohepatitis: A Post-hoc Analysis of the MAESTRO Resmetirom Trials (Phase 2/3): Cognitive Function Self-Report score(24-week) = -2.7 Point ( -4.7 to -0.6); Cognitive Function Self-Report score(24-week) = -3.0 Point ( -4.9 to -1.0).
• A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis (Phase 2/3): Proportion of Patients in the Belapectin Treatment Groups Who Develop New Esophageal Varices at 78 Weeks [18 Months] of Treatment Compared to Placebo = 56 Participants ; -; Proportion of Patients in the Belapectin Treatment Groups Who Develop New Esophageal Varices at 78 Weeks [18 Months] of Treatment Compared to Placebo = 51 Participants ; Proportion of Patients in the Belapectin Treatment Groups Who Develop New Esophageal Varices at 78 Weeks [18 Months] of Treatment Compared to Placebo = 45 Participants ; -.
• A Randomized, Double-blind, Placebo-controlled Parallel Group Phase 2a Study to Evaluate the Efficacy and Safety of HPG1860 in Subjects With Nonalcoholic Steatohepatitis (Phase 2): Safety and Tolerability of Treatment = 12 Participants ; -; Safety and Tolerability of Treatment = 13 Participants ; -; Safety and Tolerability of Treatment = 13 Participants .

These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Efimosfermin alfa (Phase 3; FGF21R).

Company & Deal Intelligence context: GSK Plc (GSK) — http://www.gsk.com.

The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.

White space around this program

1. Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
2. Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
3. Sequencing evidence: randomized data after the most relevant contemporary standard of care.
4. Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
5. Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

NCT07701993 is a focused lens on MASH Cirrhosis development. Its value will be determined by whether Efimosfermin alfa can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.